Table 2.
AhR activation | Nrf2 activation | ||||
---|---|---|---|---|---|
Cpd No. | Identity | CQ (μM) | IC50 (μM) | CQ (μM) | IC50 (μM) |
+ control | FICZ | 0.006 ± 0.000 | - | - | - |
1 | 8-desoxygartanin | 0.162 ± 0.001 | 36.00 ± 1.70 | 22.19 ± 1.24 | 49.91 ± 3.81 |
2 | gartanin | 0.412 ± 0.005 | 36.50 ± 0.71 | 9.43 ± 1.90 | 63.55 ± 1.94 |
3 | α-mangostin | 0.510 ± 0.007 | 26.30 ± 0.08 | 16.25 ± 0.46 | 24.11 ± 0.28 |
4 | 9-OHCal | 0.380 ± 0.004 | 47.60 ± 0.56 | - | 52.25 ± 3.96 |
5 | β-mangostin | 5.125 ± 0.006 | - | - | - |
6 | Garcinone D | 0.142 ± 0.008 | - | 8.08 ± 0.07 | 38.50 ± 7.27 |
7 | γ-mangostin | 0.825 ± 0.008 | 65.00 ± 3.50 | 14.93 ± 0.10 | 32.59 ± 3.96 |
CQ and IC50 are mean values ± SD of at least 2 separate experiments, each performed in triplicate. Maximum test concentrations of samples were 100 μM and 25 μM for MTT and AhR assays of pure compounds, respectively.
CQ-concentration of quadrupling; IC50- inhibitory concentration of pure compounds where the cell viability is reduced by half. Compounds with no IC50 values (−) means the compound did not exhibit >50% H1L6/HepG2-ARE cell toxicity at the concentration range tested. Compounds with no CQ values (−) for Nrf2 activation means the concentration range tested did not quadruple Nrf2 activation in HepG2-ARE cells.